Ask AI
ProCE Banner Activity

Practical Frequently Asked Questions From Pharmacists on Managing Patients With EGFR-Targeted Therapy in NSCLC

Clinical Thought

In this commentary, oncology pharmacists answer frequently asked questions about the clinical management of patients with EGFR-mutated advanced NSCLC, including biomarker testing, treatment selection, toxicity prevention, and medication access support.

Released: June 12, 2026

Share

Provided by

Provided by ProCE, LLC

ProCE Banner

Supporters

Supported by an educational grant from Johnson & Johnson.

Johnson & Johnson

Target Audience

This activity has been designed to meet the educational needs of oncology pharmacists and other healthcare professionals caring for patients with non-small-cell lung cancer. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Differentiate the TRAE profiles and mechanisms of current and emerging EGFR-targeted therapies, including TKIs, bispecific antibodies, and ADCs

  • Apply evidence-based monitoring and intervention strategies to prevent and manage dermatologic, pulmonary, hepatic, and gastrointestinal toxicities

  • Integrate pharmacist-led dose modification, sequencing, and supportive-care protocols to sustain therapy while minimizing toxicity

  • Educate patients and caregivers to enhance adherence, early symptom recognition, and shared decision-making in TRAE management

  • Collaborate with the multidisciplinary team to personalize TRAE prevention and optimize treatment outcomes in EGFR-driven NSCLC

Financial Disclosures

Primary Author

Nina DiPierro, PharmD, BCOP, has no relevant financial relationships to disclose.

Alia "Lia" Lynch, PharmD, BCOP: consultant/advisor/speaker: Amgen.